Kodiak Sciences Inc. (K27)
Summary
K27 Chart
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Sciences Inc. (K27) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kodiak Sciences Inc. ever had a stock split?
Kodiak Sciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Victor Perlroth CEO | XMUN Exchange | US50015M1099 ISIN |
| US Country | 109 Employees | - Last Dividend | - Last Split | 4 Oct 2018 IPO Date |
Overview
Kodiak Sciences Inc. is a pioneering clinical stage biopharmaceutical entity primarily focused on the discovery, development, and deployment of novel therapies aimed at treating retinal diseases, a field that requires constant innovation due to the complexity and seriousness of the conditions involved. Originally founded in 2009 under the name Oligasis, LLC, the company rebranded itself as Kodiak Sciences Inc. in 2015, situating its headquarters in Palo Alto, California. This rebranding marked a strategic shift towards leveraging advanced biotechnological processes to address some of the most challenging eye diseases, including age-related macular degeneration (AMD) and diabetic eye diseases, which significantly impair vision.
Products and Services
tarcocimab tedromer (KSI-301)
This lead product candidate stands out as a beacon of innovation within Kodiak Sciences Inc.’s portfolio. It is an anti-vascular endothelial growth factor (VEGF) antibody biopolymer, meticulously engineered to thwart the pathological angiogenesis associated with various retinal diseases. Currently, it is navigating through the rigorous phases of a Phase IIb/III clinical study for the treatment of wet age-related macular degeneration (AMD), and a separate Phase III clinical trial aimed at addressing diabetic macular edema, macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. These studies underline the broader potential of tarcocimab tedromer in revolutionizing the treatment landscape for patients suffering from these sight-threatening conditions.
KSI-501
At a preclinical stage, KSI-501 represents Kodiak's bold strides into the realm of bispecific therapeutics. This innovative candidate is a bispecific conjugate designed to tackle retinal diseases characterized by an inflammatory component. By aiming at dual targets - presumably inflammatory cytokines and angiogenic factors - KSI-501 is expected to offer a multifaceted approach to treating retinal diseases, providing hope for conditions currently deemed difficult or impossible to manage effectively.
KSI-601
KSI-601, another promising preclinical stage candidate, serves as Kodiak's answer to dry age-related macular degeneration (AMD). This ailment, characterized by the gradual loss of central vision, has long eluded effective treatment solutions. KSI-601 is conceptualized as a triplet biopolymer conjugate envisioned to address the complex pathophysiology of dry AMD, targeting multiple pathways involved in the disease's progression. Through this ambitious project, Kodiak Sciences Inc. aims to pioneer a solution that could potentially restore or preserve vision for millions affected by this debilitating condition.
